Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Adeno-associated viruses (AAVs) are among the most efficient vectors for liver gene therapy. Results obtained in the first hemophilia clinical trials demonstrated the long-term efficacy of this approach in humans, showing efficient targeting of hepatocytes with both self-complementary (sc) and single-stranded (ss) AAV vectors. However, to support clinical development of AAV-based gene therapies, efficient and scalable production processes are needed. In an effort to translate to the clinic an approach of AAV-mediated liver gene transfer to treat Crigler-Najjar (CN) syndrome, we developed an (ss)AAV8 vector carrying the human UDP-glucuronosyltransferase family 1-member A1 (hUGT1A1) transgene under the control of a liver-specific promoter. We compared our construct with similar (sc)AAV8 vectors expressing hUGT1A1, showing comparable potency in vitro and in vivo . Conversely, (ss)AAV8-hUGT1A1 vectors showed superior yields and product homogeneity compared with their (sc) counterpart. We then focused our efforts in the scale-up of a manufacturing process of the clinical product (ss)AAV8-hUGT1A1 based on the triple transfection of HEK293 cells grown in suspension. Large-scale production of this vector had characteristics identical to those of small-scale vectors produced in adherent cells. Preclinical studies in animal models of the disease and a good laboratory practice (GLP) toxicology-biodistribution study were also conducted using large-scale preparations of vectors. These studies demonstrated long-term safety and efficacy of gene transfer with (ss)AAV8-hUGT1A1 in relevant animal models of the disease, thus supporting the clinical translation of this gene therapy approach for the treatment of CN syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 3×
“(sc)AAV and (ss)AAV vectors have been used to transduce the liver in the context of several genetic disorders.(10) To this aim, the use of (sc)AAV vectors could provide potential advantages related to the bypass of the step of double-stranded DNA (dsDNA) conversion of the vg, thus facilitating the viral transduction.”
BackgroundMethodInfluentialSelf-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“To this aim, the use of (sc)AAV vectors could provide potential advantages related to the bypass of the step of double-stranded DNA (dsDNA) conversion of the vg, thus facilitating the viral transduction.(28) However, the use of (sc)AAV vectors has potential drawbacks, including the reduced genome-packaging capacity, t…”
MethodAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Self-citationGene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Self-citation
Research works printed but not linked: 28
- Crigler, 1952, Congenital familial nonhemolytic jaundice with kernicterus, Pediatrics, 10, 169
- Arias, 1969, Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity, Am. J. Med., 47, 395, 10.1016/0002-9343(69)90224-1 · DOI · Paper page
- Tu, 2012, Liver transplantation in Crigler-Najjar syndrome type I disease, HBPD INT, 11, 545
- Lysy, 2008, Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives, World J. Gastroenterol., 14, 3464, 10.3748/wjg.14.3464 · DOI
- Hafkamp, 2007, Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial, Pediatr. Res., 62, 725, 10.1203/PDR.0b013e3181598cc5 · doi:10.1203/pdr.0b013e3181598cc5
- van der Veere, 1996, Current therapy for Crigler-Najjar syndrome type 1: report of a world registry, Hepatology, 24, 311, 10.1002/hep.510240205 · DOI · Paper page
- Fagiuoli, 2013, Monogenic diseases that can be cured by liver transplantation, J. Hepatol., 59, 595, 10.1016/j.jhep.2013.04.004 · DOI · Paper page
- Junge, 2015, Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liver, J. Pediatr. Gastroenterol. Nutr., 60, 433, 10.1097/MPG.0000000000000703 · DOI
- Bortolussi, 2018, Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome, Expert Opin. Orphan Drugs, 6, 425, 10.1080/21678707.2018.1495558 · DOI
- George, 2017, Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant, N. Engl. J. Med., 377, 2215, 10.1056/NEJMoa1708538 · DOI · Paper page
- Bortolussi, 2012, Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer, FASEB J., 26, 1052, 10.1096/fj.11-195461 · DOI
- Bortolussi, 2014, Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome, Hum. Gene Ther., 25, 844, 10.1089/hum.2013.233 · DOI · Paper page
- Seppen, 2006, Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats, Mol. Ther., 13, 1085, 10.1016/j.ymthe.2006.01.014 · DOI · Paper page
- Ronzitti, 2016, A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome, Mol. Ther. Methods Clin. Dev., 3, 16049, 10.1038/mtm.2016.49 · DOI · Paper page
- 2016, Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015, Lancet HIV, 3, e361, 10.1016/S2352-3018(16)30087-X · DOI · Paper page
- Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
- Gunn, 1944, Hereditary Acholuric Jaundice in the Rat, Can. Med. Assoc. J., 50, 230
- Cornelius, 1972, Animal model of human disease. Crigler-Najjar Syndrome. Animal model: hereditary nonhemolytic unconjugated hyperbilirubinemia in Gunn rats, Am. J. Pathol., 69, 369
- Sato, 1991, Genetic defect of bilirubin UDP-glucuronosyltransferase in the hyperbilirubinemic Gunn rat, Biochem. Biophys. Res. Commun., 177, 1161, 10.1016/0006-291X(91)90661-P · doi:10.1016/0006-291x(91)90661-p
- D’Avola, 2016, Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol., 65, 776, 10.1016/j.jhep.2016.05.012 · DOI · Paper page
- Chahal, 2014, Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery, J. Virol. Methods, 196, 163, 10.1016/j.jviromet.2013.10.038 · DOI · Paper page
- Wright, 2014, AAV empty capsids: for better or for worse?, Mol. Ther., 22, 1, 10.1038/mt.2013.268 · DOI · Paper page
- Favaro, 2009, Host and vector-dependent effects on the risk of germline transmission of AAV vectors, Mol. Ther., 17, 1022, 10.1038/mt.2009.56 · DOI · Paper page
- Davidoff, 2005, Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models, Mol. Ther., 11, 875, 10.1016/j.ymthe.2004.12.022 · DOI · Paper page
- Snyder, 1997, Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice, Hum. Gene Ther., 8, 1891, 10.1089/hum.1997.8.16-1891 · DOI · Paper page
- Thummel, 1982, Construction of adenovirus expression vectors by site-directed in vivo recombination, J. Mol. Appl. Genet., 1, 435
- Meliani, 2017, Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors, Blood Adv., 1, 2019, 10.1182/bloodadvances.2017010181 · DOI · Paper page
- Montenegro-Miranda, 2013, Adeno-associated viral vector serotype 5 poorly transduces liver in rat models, PLoS ONE, 8, e82597, 10.1371/journal.pone.0082597 · DOI
Cited by
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
Self-citationCosta-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
Self-citationAAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Self-citation
Metadata
- Authors
- Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., Dufour, D. G., Lacoste, F., Luc, C., Wittenberghe, L. V., Martin, S., Le Bec, C., Bosma, P. J., Muro, A. F., Ronzitti, G., Hebben, M., & Mingozzi, F.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 12
- Pages
- 157-174
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2907308363
- Cited by
- 63
- References
- 18
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- European Union’s H2020 (755225)
- Genethon
- Association Française contre les Myopathies
- CIAMI Association of Crigler-Najjar patients Italy
- Conseil Départemental de l'Essonne
- ZonMW TGO
- Najjar Fund
- Beneficentia Stiftung
- EU Marie Slodowska-Curie (658712-3)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. https://app.cochat.ai/papers/10.1016/j.omtm.2018.12.011
- The paper
- Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., Dufour, D. G., Lacoste, F., Luc, C., Wittenberghe, L. V., Martin, S., Le Bec, C., Bosma, P. J., Muro, A. F., Ronzitti, G., . . . Mingozzi, F. (2019). Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2018.12.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.